Cargando…

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products

Natural products originating from marine and plant materials are a rich source of chemical diversity and unique antimicrobials. Using an established in vitro model of HIV-1 latency, we screened 257 pure compounds from a marine natural product library and identified 4 (psammaplin A, aplysiatoxin, deb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richard, Khumoekae, Williams, David E., de Silva, E. Dilip, Brockman, Mark A., Brumme, Zabrina L., Andersen, Raymond J., Tietjen, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071113/ https://www.ncbi.nlm.nih.gov/pubmed/29954099 http://dx.doi.org/10.3390/v10070348

Ejemplares similares

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
por: Divsalar, Donya Naz, et al.
Publicado: (2020)

Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors
por: Tietjen, Ian, et al.
Publicado: (2015)

CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells
por: Horvath, Riley M., et al.
Publicado: (2023)

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs
por: Brockman, Mark A., et al.
Publicado: (2015)

Naturally-arising amino acid polymorphisms of HIV-1 Nef that differentially modulate downregulation of HLA-A and HLA-B molecules
por: Mahiti, Macdonald, et al.
Publicado: (2013)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences
por: Mahiti, Macdonald, et al.
Publicado: (2016)

Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity
por: Jin, Steven W., et al.
Publicado: (2019)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
por: Kim, Jocelyn T., et al.
Publicado: (2022)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
por: Relaño-Rodríguez, Ignacio, et al.
Publicado: (2019)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
por: Ait-Ammar, Amina, et al.
Publicado: (2020)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification
por: Brumme, Zabrina L., et al.
Publicado: (2009)

Anti-latency agents to purge HIV reservoirs
por: Moreno, Santiago
Publicado: (2012)

Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV
por: Ghofrani, Joshua, et al.
Publicado: (2023)

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents
por: Campos Coelho, Antonio Victor, et al.
Publicado: (2020)

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
por: Matsuda, Kouki, et al.
Publicado: (2021)

Opioid use does not limit potent low-dose HIV-1 latency reversal agent boosting
por: Lilie, Tyler, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8d0maf5n22de6frdb7hq6q5e58